Anti-flotillin-1/2 antibodies in a patient with neurogenic muscle atrophy and mild neuropsychological impairment
-
Published:2022-09-22
Issue:1
Volume:4
Page:
-
ISSN:2524-3489
-
Container-title:Neurological Research and Practice
-
language:en
-
Short-container-title:Neurol. Res. Pract.
Author:
Wagner-Altendorf Tobias A.ORCID, Wandinger Klaus-Peter, Markewitz Robert, Antufjew Anna, Boppel Tobias, Münte Thomas F.
Abstract
AbstractAutoimmune-mediated neural inflammation can affect both the central and the peripheral nervous system. Recently, antibodies against the peripheral membrane protein flotillin have been described in patients with multiple sclerosis, limbic encephalitis and sensorimotor demyelinating polyneuropathy. Here, we report the case of a 75-year-old male patient presenting with slowly progressive muscle weakness, as well as mild cognitive impairment. MR neurography of the leg showed fascicular enlargement and inflammation of ischiadic nerve fibers, while cerebral MRI showed bilateral hippocampal atrophy. Serological testing revealed positive anti-flotillin-1/2 antibodies in serum (1:100) and CSF (1:1). Assuming autoimmune anti-flotillin antibody-associated neurogenic muscle atrophy, the patient was treated with immunoglobulins, which led to a clinical improvement of muscle weakness. In light of the positive anti-flotillin antibodies and the local CNS immunoglobulin production, the mild cognitive impairment and hippocampal atrophy were interpreted as a cerebral involvement in the sense of a subclinical limbic encephalitis. We conclude that anti-flotillin antibodies can be associated with central and peripheral nervous system autoimmunity and should be considered in diagnostical workup.
Publisher
Springer Science and Business Media LLC
Subject
Automotive Engineering
Reference12 articles.
1. Abdullah, M., Kimura, N., Akatsu, H., Hashizume, Y., Ferdous, T., Tachita, T., Iida, S., Zou, K., Matsubara, E., & Michikawa, M. (2019). Flotillin is a novel diagnostic blood marker of Alzheimer’s disease. Journal of Alzheimer’s Disease, 72(4), 1165–1176. 2. Angelopoulou, E., Paudel, Y. N., Shaikh, M., & Piperi, C. (2020). Flotillin: a promising biomarker for alzheimer’s disease. Journal of Personalized Medicine, 10(2), 20. 3. Bitsikas, V., Riento, K., Howe, J. D., Barry, N. P., & Nichols, B. J. (2014). The role of flotillins in regulating Aβ production, investigated using Flotillin 1-/-, Flotillin 2-/-double knockout mice. PloS one, 9(1), e85217. 4. Buleu, C., Zechel, S., Abdelnaby, R., Schmidt, K., Borowski, K., & Zschüntzsch, J. (2019). Fallbericht eines Patienten mit dem Nachweis von anti-Flotillin-1/2-Antikörpern bei einer sensomotorischen demyelinisierenden Polyneuropathie. Nervenheilkunde, 38(05), P88. 5. Gauthier-Rouvière, C., Bodin, S., Comunale, F., & Planchon, D. (2020). Flotillin membrane domains in cancer. Cancer and Metastasis Reviews, 39, 361–374.
|
|